Curis (NASDAQ: CRIS)
Curis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Curis Company Info
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
News & Analysis
Curis (CRIS) Q2 Loss Narrows 66%
Why Curis Stock Perked Up in August
The biotech's shares rode the wave of buyout speculation higher last month.
Why Curis Fell Off a Cliff on Friday
The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial.
Why Curis Stock Crashed on Thursday
The swoon came shortly after some very good news for the company.
Why Curis, Inc. Is Soaring Today
Traders cheer after the company reports upbeat regulatory news. Here's what investors need to know.
Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
The biopharma reported second-quarter 2017 earnings and data from a key mid-stage trial.
3 Top Stocks Under $5
Cheap stocks are often cheap for a reason, but sometimes the market has mispriced their potential.
Today’s Top Biotech Stories: Curis, Amgen, and Novartis
Curis, Amgen, CytRx, and Novartis could make waves in the biotech sector this morning.
Valuation
Earnings Transcripts
Curis (CRIS) Q2 2022 Earnings Call Transcript
CRIS earnings call for the period ending June 30, 2022.
Curis (CRIS) Q1 2022 Earnings Call Transcript
CRIS earnings call for the period ending March 31, 2022.
Curis (CRIS) Q4 2021 Earnings Call Transcript
CRIS earnings call for the period ending December 31, 2021.
Curis (CRIS) Q3 2021 Earnings Call Transcript
CRIS earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.